NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
72 trialsNCT03924869 2025-12-11
KEYNOTE-867
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT06280196 2025-12-02
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions
Phase 3 Terminated
NCT06643117 2025-06-26
Lotus
Formycon AG
Phase 3 Terminated
NCT04588246 2025-06-06
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT04316013 2025-03-14
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Peter MacCallum Cancer Centre, Australia
Phase 3 Terminated
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT02887521 2025-02-03
Pulmonary Rehabilitation Before Lung Cancer Resection
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT04866017 2024-10-31
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT03447769 2024-10-09
Canopy-A
Novartis
Phase 3 Terminated
NCT02974426 2024-06-12
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 3 Terminated
NCT03866980 2024-04-03
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Akeso
Phase 3 Terminated
NCT00310232 2024-04-02
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Terminated
NCT04171284 2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd.
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT02826161 2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT03515629 2022-11-16
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 3 Terminated
NCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT02768558 2021-06-02
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
RTOG Foundation, Inc.
Phase 3 Terminated
NCT00662597 2020-12-24
ATRACT-1
Novartis
Phase 3 Terminated
NCT00738387 2020-12-24
ATTRACT-2
Novartis
Phase 3 Terminated
NCT00269828 2020-11-24
PIONEER
CTI BioPharma
Phase 3 Terminated
NCT00054197 2020-10-05
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT00551733 2020-10-05
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT03745222 2020-07-15
RATIONALE001
Celgene
Phase 3 Terminated
NCT02187367 2019-09-10
EGF
Bioven Sdn. Bhd.
Phase 3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02409355 2019-02-15
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Hoffmann-La Roche
Phase 3 Terminated
NCT02162537 2019-02-01
METAL2
Centre Hospitalier Intercommunal Creteil
Phase 3 Terminated
NCT01058759 2018-08-22
Taxotere-Enoxaparin-(ENOXA)-Study
Hannover Medical School
Phase 3 Terminated
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT02049151 2017-08-23
START2
EMD Serono
Phase 3 Terminated
NCT01336894 2017-05-30
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00526643 2017-03-28
CAPPA-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT00745797 2017-03-06
PCI
Chinese Society of Lung Cancer
Phase 3 Terminated
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT01798485 2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3 Terminated
NCT02629848 2015-12-14
Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
Takeda
Phase 3 Terminated
NCT00738881 2015-10-29
MARVEL
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00460317 2015-09-07
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Amgen
Phase 3 Terminated
NCT01444118 2015-07-22
NSCLC
Bioven Sdn. Bhd.
Phase 3 Terminated
NCT01282151 2015-07-14
TRAIL
Chonnam National University Hospital
Phase 3 Terminated
NCT01379976 2015-04-24
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer
Mario Negri Institute for Pharmacological Research
Phase 3 Terminated